Defendant
11 cases as defendant.
Follow-on antitrust suit alleging Sherman Act § 2 monopolization. Complaint alleges the '427 was expressly taught in prior art and issued after a purportedly false Tutino Declaration, and that Celgene withdrew its '427 infringement claims before most settlements.
Antitrust monopolization suit challenging Celgene's Pomalyst crystalline-form patents, including the '647/'648/'649 patents; Celgene/BMS moved to dismiss.
Antitrust/purchaser-overcharge action against Celgene and Bristol Myers Squibb. The complaint references the '3939 patent and the method-of-treatment patent tree as part of the alleged monopolization scheme. Case is pending.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; CenterWell Pharmacy sued Celgene in S.D.N.Y. Status is generally pending/consolidated.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; plaintiff sued Celgene in S.D.N.Y. Status is generally pending/consolidated.
Antitrust/purchaser-overcharge action against Celgene. The '3939 patent is expressly identified in the complaint as part of the alleged monopolization scheme concerning pomalidomide. Case is pending.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; Blue Cross LA sued Celgene in S.D.N.Y. Status is generally pending/consolidated.
Antitrust/purchaser-overcharge action alleging monopolization of pomalidomide. The '3939 patent is cited in the complaint as part of the alleged scheme to delay generic entry. Motion to dismiss denied in part; proceeding.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; Molina Healthcare sued Celgene in D.N.J. Status is generally pending/consolidated.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; MSP Recovery Claims sued Celgene in D.N.J. Status is generally pending/consolidated.
CenterWell filed monopolization claims under Section 2 of the Sherman Act against Celgene and Bristol Myers Squibb, citing the '647/'648/'649 patents as part of an alleged pay-for-delay scheme.